OpenNashEarnings

Pharmaceuticals · NYSE: AZN

AstraZeneca earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 9 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

AstraZeneca is pairing its antibody-drug conjugates with Summit's ivonescimab via a $2bn equity stake, while 12 positive Phase III readouts widen its late-stage pipeline.

Demand is broad across cancer, respiratory and rare disease. Imfinzi, Enhertu, Tezspire and Ultomiris keep widening into earlier treatment settings, and four new medicines won their first approvals, including Etcamah and Baxfendy. The Baxfendy hypertension launch has reached 12,000 new patient starts, mostly in commercial plans. Tagrisso is being extended with Orpathys, and Datroway is gaining ground in breast and lung cancer. Farxiga and Brilinta generic competition is the main drag.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗

Quarters

KPI history

20-F filings